Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research In Vitro Pomaglumetad methionil (LY2140023) is a high-affinity peptide transporter 1 (PEPT1) substrate with a K m value of ~30 µM. LY2140023 is active against [ 14 C]Gly-Sar with an IC 50 value of 0.018 mM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Pomaglumetad methionil (LY2140023; orally; 3-300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Fischer rats (approximately 250 g) Dosage: 3 mg/kg, 10 mg/kg, and 300 mg/kg Administration: Orally; once daily for 7 days Result: Dose-dependent increased the levels of the dopamine metabolites DOPAC and HVA. Form:Solid IC50& Target:mGluR2 mGluR3